| Literature DB >> 19696193 |
Tamara Regina Calvo1, Cássia Regina Primila Cardoso, Adriana Candido da Silva Moura, Lourdes Campaner Dos Santos, Ilce Mara Syllos Colus, Wagner Vilegas, Eliana Aparecida Varanda.
Abstract
Indigofera truxillensis and I. suffruticosa, are used as a source of indigo dye and to treat several diseases. The mutagenic activity of the methanolic extracts from aerial parts, glycerolipid, flavonoid and alkaloid fractions of the extract were evaluated by means of Salmonella/microsome assays using TA100, TA98, TA102 and TA97a strains. The methanolic extract of I. truxillensis showed mutagenic activity in the TA98 strain without S9 while glycerolipid fraction was devoid of activity. The flavonoid and alkaloid fractions of both plants showed mutagenicity. Chemical analysis of flavonoid fractions of I. truxillensis and I. suffruticosa resulted in the identification of kaempferol, quercetin and their derivatives. The alkaloid fraction of both the species contained indigo and indirubin and indigo was found mainly responsible for the mutagenic activity.Entities:
Year: 2011 PMID: 19696193 PMCID: PMC3135973 DOI: 10.1093/ecam/nep123
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Structures of the compounds isolated from the Indigofera species. Fraction B (Flavonoid fraction): I. truxillensis—kaempferol 3-O-α-l-rhamnopyranoside (It1) and kaempferol 7-O-α-l-rhamnopyranoside (It2), kaempferol 3-O-α-l-rhamnopyranoside-7-O-α-l-rhamnopyranoside (It3) and kaempferol 3-O-α-l-arabinopyranoside-7-O-α-l-rhamnopyranoside (It4); I. suffruticosa—quercetin 7-O-β-d-glucopyranoside (Is1), quercetin 3-O-[β-d-xylopyranosyl-(1→2)-β-d-galactopyranoside] (Is2), quercetin 3-O-[α-l-rhamnopyranosyl-(1→6)-β-d-glucopyranoside] (Is3) and quercetin 3-O-[β-d-glucopyranosyl-(1→2)-β-d-glucopyranoside] (Is4). Fraction C (Alkaloid fraction): I. truxillensis and I. suffruticosa—indigo (It5, Is5) and indirubin (It6, Is6).
Mutagenic activity expressed as the mean and SD of the number of revertants/plate in bacterial strains TA98, TA100, TA97a and TA102 exposed to MeOH extract and fractions A, B and C of I. truxillensis at various doses, with (+S9) or without (−S9) metabolic activation.
| Treatments mg/plate | Revertants/plate in | |||||||
|---|---|---|---|---|---|---|---|---|
| TA98 | TA97a | TA100 | TA102 | |||||
| −S9(a) | +S9(b) | −S9(a) | +S9(b) | −S9(c) | +S9(b) | −S9(d) | +S9(b) | |
| MeOH extract | ||||||||
| 0 | 43 ± 2.7 | 36 ± 2.0 | 131 ± 1.5 | 139 ± 2.5 | 163 ± 4.2 | 145 ± 9.5 | 242 ± 9.2 | 223 ± 11.9 |
| 1.25 | 55 ± 4.6* (1.3) | 41 ± 2.3 (1.1) | 143 ± 5.0 (1.1) | 131 ± 2.5 (0.9) | 184 ± 8.7 (1.1) | 151 ± 14.5 (1.0) | 271 ± 4.0 (1.1) | 219 ± 7.9 (0.9) |
| 2.50 | 57 ± 1.5** (1.3) | 38 ± 7.6 (1.1) | 143 ± 3.1 (1.1) | 129 ± 10.7 (0.9) | 186 ± 7.6 (1.1) | 145 ± 3.0 (1.0) | 254 ± 1.5 (1.0) | 223 ± 11.0 (1.0) |
| 3.75 | 87 ± 2.0** (2.0) | 42 ± 2.0 (1.3) | 147 ± 2.1 (1.1) | 137 ± 6.8 (0.9) | 194 ± 4.0 (1.2) | 149 ± 11.9 (1.0) | 258 ± 1.0 (1.1) | 238 ± 6.7 (1.1) |
| 5.00 | 77 ± 6.1** (1.8) | 45 ± 4.2 (1.3) | 148 ± 5.0 (1.1) | 142 ± 16.1 (1.0) | 180 ± 6.2 (1.1) | 141 ± 7.6 (0.9) | 264 ± 4.0 (1.1) | 228 ± 5.3 (1.0) |
| 7.50 | 75 ± 5.0** (1.7) | 51 ± 3.1(1.4) | 159 ± 7.8 (1.2) | 134 ± 16.0 (0.9) | 173 ± 5.0 (1.1) | 140 ± 5.5 (0.9) | 280 ± 35.6 (1.2) | 249 ± 11.0 (1.1) |
| Fraction A (glycerolipids) | ||||||||
| 0 | 29 ± 2,1 | 31 ± 2.7 | 141 ± 8.0 | 143 ± 4.0 | 148 ± 2.5 | 143 ± 5.0 | 239 ± 16.7 | 210 ± 11.1 |
| 0.12 | 38 ± 4.6 (1.3) | 31 ± 3.6 (1.0) | 143 ± 13.5 (1.0) | 137 ± 5.3 (0.9) | 163 ± 26.1 (1.1) | 155 ± 4.2 (1.1) | 267 ± 14.1 (1.1) | 235 ± 13.1 (1.1) |
| 0.38 | 32 ± 5.3 (1.1) | 30 ± 1.5 (0.9) | 138 ± 4.6 (0.9) | 143 ± 4.0 (1.0) | 151 ± 4.2 (1.0) | 149 ± 7.0 (1.0) | 247 ± 7.6 (1.0) | 236 ± 10.3 (1.1) |
| 0.75 | 42 ± 13.5 (1.4) | 40 ± 4.5 (1.3) | 132 ± 7.8 (0.9) | 148 ± 3.6 (1.0) | 164 ± 13.9 (1.1) | 165 ± 13.6 (1.2) | 245 ± 5.9 (1.0) | 251 ± 5.1 (1.2) |
| 1.50 | 39 ± 5.6 (1.3) | 35 ± 3.6 (1.1) | 144 ± 8.4 (1.0) | 138 ± 7.6 (0.9) | 183 ± 14.1 (1.2) | 166 ± 3.1 (1.2) | 250 ± 6.1 (1.0) | 254 ± 5.6 (1.2) |
| 2.50 | 40 ± 4.1 (1.4) | 39 ± 6.0 (1.3) | 138 ± 4.6 (0.9) | 143 ± 6.1 (1.0) | 173 ± 10.1 (1.2) | 175 ± 7.6 (1.2) | 251 ± 6.9 (1.0) | 255 ± 7.2 (1.2) |
| Fraction B (flavonoids) | ||||||||
| 0 | 29 ± 2,1 | 31 ± 2.7 | 141 ± 8.0 | 143 ± 4.0 | 148 ± 2.5 | 143 ± 5.0 | 239 ± 16.7 | 210 ± 11.1 |
| 0.12 | 32 ± 4.0 (1.1) | 30 ± 5.9 (0.9) | 142 ± 20.0 (1.0) | 145 ± 7.9 (1.0) | 144 ± 14.2 (0.9) | 145 ± 4.2 (1.0) | 223 ± 11.0 (0.9) | 224 ± 6.0 (1.1) |
| 0.38 | 40 ± 2.5* (1.4) | 40 ± 8.7 (1.3) | 132 ± 7.0 (0.9) | 142 ± 3.1 (0.9) | 140 ± 1.5 (0.9) | 145 ± 6.5 (1.0) | 198 ± 12.5 (0.8) | 206 ± 11.4 (0.9) |
| 0.75 | 42 ± 4.0** (1.4) | 40 ± 7.5 (1.3) | 138 ± 3.6 (0.9) | 146 ± 5.1 (1.0) | 145 ± 13.2 (0.9) | 156 ± 12.4 (1.1) | 213 ± 23.3 (0.9) | 216 ± 17.1 (1.0) |
| 1.50 | 50 ± 4.9** (1.7) | 49 ± 6.4* (1.6) | 156 ± 9.3 (1.1) | 146 ± 5.9 (1.0) | 155 ± 5.0 (1.0) | 154 ± 6.5 (1.1) | 246 ± 7.4 (1.0) | 232 ± 13.6 (1.1) |
| 2.50 | 57 ± 5.0**(1.9) | 49 ± 4.6* (1.6) | 158 ± 3.2 (1.1) | 151 ± 7.8 (1.1) | 136 ± 4.6 (0.9) | 142 ± 7.9 (0.9) | 250 ± 8.5 (1.0) | 234 ± 11.0 (1.1) |
| Fraction C (alkaloids) | ||||||||
| 0 | 43 ± 2.7 | 36 ± 2.0 | 131 ± 1.5 | 139 ± 2.5 | 163 ± 4.2 | 145 ± 9.5 | 242 ± 9.2 | 223 ± 11.9 |
| 0.12 | 37 ± 4.0 (0.9) | 33 ± 5.0 (0.9) | 133 ± 4.5 (1.0) | 126 ± 6.6 (0.9) | 165 ± 3.6 (1.0) | 132 ± 3.1 (0.9) | 241 ± 7.1 (0.9) | 220 ± 4.5 (0.9) |
| 0.38 | 43 ± 2.5 (1.0) | 36 ± 6.0 (1.0) | 146 ± 7.0 (1.1) | 136 ± 9.1 (0.9) | 178 ± 3.1 (1.1) | 142 ± 2.0 (0.9) | 256 ± 21.6 (1.1) | 224 ± 9.9 (1.0) |
| 0.75 | 44 ± 1.5 (1.0) | 34 ± 11.1 (0.9) | 136 ± 8.6 (1.0) | 133 ± 4.5 (0.9) | 183 ± 4.0 (1.1) | 144 ± 4.6 (0.9) | 294 ± 12.9 (1.2) | 223 ± 14.1 (1.0) |
| 1.50 | 72 ± 9.7* (1.7) | 45 ± 3.1 (1.3) | 152 ± 13.1 (1.2) | 146 ± 4.0 (1.1) | 189 ± 3.5 (1.1) | 141 ± 10.0 (0.9) | 310 ± 2.0 (1.3) | 224 ± 11.2 (1.0) |
| Control + | 608 ± 71.52 | 663 ± 35.4 | 711 ± 12.1 | 761 ± 28.0 | 914 ± 17.6 | 886 ± 49.3 | 1076 ± 57.1 | 1082 ± 72.9 |
MeOH: methanolic extract; 0 = negative control (DMSO—100 μl/plate); Control +: Positive control.
(a)4-Nitro-o-phenylenediamine (10.0 μg/plate); (b)2-anthramine (1.25 μg/plate); (c)Sodium azide (1.25 μg/plate); (d)Mitomycin C (0.5 μg/plate).
*P < .05, **P < .01 (ANOVA). The values in brackets are MI values.
Mutagenic activity expressed as the mean and SD of the number of revertants/plate in bacterial strains TA98, TA100, TA97a and TA102 exposed to MeOH extract and fractions A, B and C of I. suffruticosa, at various doses, with (+S9) or without (−S9) metabolic activation.
| Treatments mg/plate | Revertants/plate in | |||||||
|---|---|---|---|---|---|---|---|---|
| TA98 | TA97a | TA100 | TA102 | |||||
| −S9(a) | +S9(b) | −S9(a) | +S9(b) | −S9(c) | +S9(b) | −S9(d) | +S9(b) | |
| MeOH extract | ||||||||
| 0 | 43 ± 2.7 | 36 ± 2.0 | 131 ± 1.5 | 139 ± 2.5 | 163 ± 4.2 | 145 ± 9.5 | 242 ± 9.2 | 223 ± 11.9 |
| 1.25 | 38 ± 4.6 (0.9) | 41 ± 1.2 (1.1) | 145 ± 3.1 (1.1) | 138 ± 2.1 (0.9) | 152 ± 4.0 (0.9) | 141 ± 2.1 (0.9) | 262 ± 2.5 (1.1) | 219 ± 4.9 (0.9) |
| 2.50 | 43 ± 4.5 (1.0) | 40 ± 2.7 (1.1) | 145 ± 2.1 (1.1) | 142 ± 4.2 (1.0) | 151 ± 2.1 (0.9) | 147 ± 6.7 (1.0) | 244 ± 7.6 (1.0) | 225 ± 8.5 (1.0) |
| 3.75 | 62 ± 2.5** (1.4) | 44 ± 3.1 (1.2) | 147 ± 4.0 (1.1) | 145 ± 2.1 (1.0) | 161 ± 2.7 (0.9) | 146 ± 7.5 (1.0) | 249 ± 6.7 (1.0) | 242 ± 5.0 (1.1) |
| 5.00 | 66 ± 1.5** (1.5) | 44 ± 3.1 (1.2) | 153 ± 5.0 (1.2) | 142 ± 6.4 (1.0) | 165 ± 3.1 (1.0) | 152 ± 6.2 (1.0) | 250 ± 6.1 (1.0) | 234 ± 7.9 (1.0) |
| 7.50 | 76 ± 5.9** (1.8) | 45 ± 3.5 (1.2) | 159 ± 7.8 (1.2) | 151 ± 5.1 (1.0) | 156 ± 1.5 (0.9) | 149 ± 6.0 (1.0) | 253 ± 3.5 (1.0) | 237 ± 9.6 (1.1) |
| Fraction A (glycerolipids) | ||||||||
| 0 | 43 ± 2.7 | 36 ± 2.0 | 131 ± 1.5 | 139 ± 2.5 | 148 ± 2.5 | 143 ± 5.0 | 239 ± 16.7 | 210 ± 11.1 |
| 0.12 | 46 ± 1.7 (1.1) | 35 ± 2.0 (0.9) | 131 ± 2.1 (1.0) | 136 ± 3.5 (0.9) | 159 ± 4.2 (1.1) | 145 ± 3.0 (1.0) | 251 ± 7.0 (1.1) | 227 ± 7.6 (1.1) |
| 0.38 | 47 ± 1.5 (1.1) | 38 ± 2.5 (1.1) | 134 ± 3.1 (1.0) | 135 ± 3.1 (0.9) | 160 ± 2.0 (1.1) | 147 ± 3.1 (1.0) | 260 ± 6.0 (1.1) | 235 ± 5.0 (1.1) |
| 0.75 | 50 ± 1.5 (1.2) | 42 ± 1.5 (1.2) | 139 ± 5.0 (1.1) | 138 ± 1.2 (0.9) | 163 ± 3.1 (1.1) | 152 ± 2.1 (1.1) | 264 ± 8.4 (1.1) | 247 ± 5.0 (1.2) |
| 1.50 | 55 ± 3.6 (1.1) | 45 ± 1.6 (1.3) | 143 ± 2.5 (1.1) | 142 ± 2.1 (1.0) | 170 ± 1.5 (1.1) | 160 ± 2.0 (1.1) | 265 ± 5.0 (1.1) | 255 ± 5.0 (1.2) |
| Fraction B (flavonoids) | ||||||||
| 0 | 43 ± 2.7 | 36 ± 2.0 | 131 ± 1.5 | 139 ± 2.5 | 148 ± 2.5 | 143 ± 5.0 | 239 ± 16.7 | 210 ± 11.1 |
| 0.12 | 45 ± 1.5 (1.0) | 42 ± 2.0 (1.2) | 142 ± 1.5 (1.0) | 136 ± 2.0 (1.0) | 149 ± 4.2 (1.0) | 136 ± 3.1 (0.9) | 244 ± 3.2 (1.0) | 219 ± 8.1 (1.0) |
| 0.38 | 52 ± 1.5* (1.2) | 43 ± 4.5 (1.2) | 142 ± 1.0 (1.0) | 139 ± 1.5 (1.0) | 152 ± 3.6 (1.0) | 140 ± 2.5 (0.9) | 249 ± 2.1 (1.0) | 239 ± 6.1 (1.1) |
| 0.75 | 63 ± 3.1** (1.5) | 48 ± 1.2** (1.3) | 144 ± 3.1 (1.1) | 141 ± 2.1 (1.0) | 153 ± 5.5 (1.0) | 142 ± 2.1 (0.9) | 248 ± 26.2 (1.0) | 243 ± 5.0 (1.2) |
| 1.50 | 81 ± 1.5** (1.9) | 54 ± 2.5**(1.5) | 149 ± 1.5 (1.1) | 144 ± 3.2 (1.0) | 158 ± 2.0 (1.1) | 143 ± 2.0 (1.0) | 272 ± 6.2 (1.1) | 264 ± 4.7 (1.3) |
| Fraction C (alkaloids) | ||||||||
| 0 | 43 ± 2.7 | 36 ± 2.0 | 131 ± 1.5 | 139 ± 2.5 | 148 ± 2.5 | 143 ± 5.0 | 239 ± 16.7 | 210 ± 11.1 |
| 0.12 | 46 ± 1.5 (1.1) | 31 ± 1.7 (0.9) | 142 ± 2.0 (1.0) | 139 ± 1.2 (1.0) | 151 ± 2.3 (1.0) | 140 ± 2.7 (0.9) | 255 ± 4.2 (1.1) | 228 ± 5.7 (1.1) |
| 0.38 | 50 ± 2.0 (1.2) | 38 ± 1.5 (1.1) | 146 ± 1.2 (1.1) | 139 ± 3.1 (1.0) | 153 ± 2.5 (1.0) | 145 ± 3.0 (1.0) | 269 ± 1.2 (1.1) | 239 ± 4.2 (1.1) |
| 0.75 | 69 ± 1.2* (1.6) | 40 ± 1.5 (1.1) | 152 ± 2.0 (1.0) | 143 ± 3.1 (1.0) | 165 ± 3.8 (1.1) | 149 ± 2.1 (1.0) | 278 ± 5.3 (1.2) | 243 ± 5.9 (1.2) |
| 1.50 | 85 ± 1.5**(1.9) | 47 ± 1.2 (1.3) | 152 ± 4.4 (1.2) | 143 ± 1.5 (1.1) | 180 ± 2.0 (1.2) | 154 ± 2.5 (1.1) | 306 ± 7.2 (1.3) | 255 ± 4.7 (1.2) |
| Control + | 466 ± 34.1 | 607 ± 30.3 | 703 ± 24.7 | 750 ± 55.7 | 955 ± 33.0 | 797 ± 32.1 | 1158 ± 65.8 | 1158 ± 49.4 |
MeOH: methanolic extract; 0 = negative control (DMSO—100 μl/plate); Control +: positive control.
(a)4-Nitro-o-phenylenediamine (5.0 μg/plate); (b)2-anthramine (1.25 μg/plate); (c)Sodium azide (1.25 μg/plate); (d)Mitomycin C (0.5 μg/plate).
*P < .05, **P < .01 (ANOVA). The values in brackets are MI values.
Mutagenic activity expressed as the mean and SD of the number of revertants/plate in bacterial strain TA98 exposed to the compounds isolated from methanolic extract of I. truxillensis and I. suffruticosa at various doses, with (+S9) or without (−S9) metabolic activation.
| Treatment (mg/plate) | TA98 (−S9) | TA98 (+S9) |
|---|---|---|
| Positive control | 867 ± 1.4 | 991 ± 10.1 |
| Negative control | 30 ± 1.5 | 36 ± 4.0 |
| Alkaloids | ||
|
| ||
| 0.125 | 38 ± 0.6 (1.3) | 44 ± 2.7* (1.2) |
| 0.25 | 42 ± 3.2 (1.4) | 86 ± 5.3** (2.4) |
| 0.50 | 45 ± 1.5 (1.5) | 192 ± 2.5** (5.3) |
| 0.75 | 50 ± 4.0* (1.7) | 229 ± 3.6** (6.7) |
| 1.00 | 57 ± 4.2** (1.9) | 276 ± 5.3** (7.7) |
|
| ||
| 0.125 | 46 ± 2.7 (1.5) | 36 ± 2.0 (1.0) |
| 0.25 | 58 ± 3.8** (1.9) | 36 ± 4.0 (1.0) |
| 0.50 | 58 ± 3.0** (1.9) | 38 ± 2.5 (1.1) |
| 0.75 | 63 ± 1.7** (2.1) | 43 ± 4.0 (1.2) |
| 1.00 | 63 ± 3.6** (2.1) | 46 ± 3.6 (1.3) |
Negative control: DMSO (100 μl/plate); Positive control: −S9: 4-nitro-o-phenylenediamine (10.0 μg/plate); +S9: 2-anthramine (1.25 μg/plate).
*P < .05, **P < .01 (ANOVA). The values in brackets are MI values.